Pasar al contenido principal

IDENTIFICACION DE BIOMARCADORES NO INVASIVOS DE REVERSION EN LA ENFERMEDAD HEPATICA POR ALCOHOL A TRAVES DEL ESTUDIO: VESICULAS EXTRACELULARES Y PARAMETROS HEMODINÁMICOS.

PI21/01995

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality

  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Martí-Aguado, D.|||0000-0002-4266-6076
  • Gómez-Medina, C.|||0000-0002-4788-5630
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Szafranska, Justyna|||0000-0003-0467-8479
  • Brujats Rubirola, Anna|||0000-0003-3317-0295
  • Osuna Gómez, Rubén|||0000-0003-2875-4405
  • Alfaro-Cervelló, C.|||0000-0002-3737-4028
  • Pose, Elisa|||0000-0002-0224-7686
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Fernández-Carrillo, C.|||0000-0002-1326-5142
  • Cabezas González, Joaquín|||0000-0003-0012-484X
  • López-Pelayo, Hugo|||0000-0002-3850-8374
  • Arab, Juan Pablo|||0000-0002-8561-396X
  • Argemi, J.|||0000-0003-1696-7753
  • Bataller, Ramon|||0000-0002-1119-7799
  • Guinart Cuadra, Albert|||0000-0003-0233-5595
  • Clemente-Sanchez, Ana
  • Contreras, Cynthia
Background and Aims: Alcohol use disorder has been reported in patients undergoing bariatric procedures, but the pattern of alcohol consumption has not been evaluated. We investigated the prevalence, risk factors, and impact of binge drinking (BD) at the time of surgery and during follow-up. Methods: A prospective, longitudinal study of subjects undergoing bariatric surgery was included in the LABS-2 registry between 2006 and 2009. Participants with AUDIT questionnaire at the time of surgery and a minimum of 12 months follow-up were included. BD was defined as consuming ≥5 drinks on at least 1 occasion in the previous month. Liver biopsies were obtained during bariatric procedures in not all cases. Survival analysis was performed with the adjusted Cox regression model and competing risk. Results: A total of 2257 subjects were included, with a median follow-up of 79 months. The prevalence of BD at time of surgery was 12%, and it raised up to 23% during follow-up. Patients with BD predominantly had a binge eating disorder (OR=1.35 [95% CI: 1.04-1.76]), regularly consumed fast food [OR=1.4 (95% CI: 1.07-1.85)] and used other drugs (OR=2.65 [95% CI: 1.74-4.04]). Within liver biopsies evaluation, BD showed higher hepatic iron deposits (OR=3.00 [95% CI: 1.25-7.21]). BD at the time of surgery was associated with a higher risk of BD during follow-up (OR=10.49 [95% CI: 7.86-14.00]) and long-term mortality (HR: 3.21 [95% CI: 1.67-6.18]). Specific causes of death in these patients with BD were liver disease (p=0.020), suicide (p=0.015), neoplasms (p=0.034), and respiratory (p=0.025). Conclusions: The prevalence of BD in patients undergoing bariatric surgery is high and increases the risk of postoperative liver disease, suicides, and long-term mortality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In Vitro Immune Response of Mononuclear Cells to Multidrug-Resistant Escherichia coli

  • Cuyàs, Berta|||0000-0001-9988-7163
  • Cantó, Elisabet|||0000-0002-1782-1855
  • Sánchez, Elisabet|||0000-0002-3280-9301
  • Miró, Elisenda|||0000-0003-2781-6926
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Roman, Eva|||0000-0001-9084-8555
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Escorsell, Àngels|||0000-0001-5083-8467
  • Vidal, Silvia|||0000-0002-3909-6682
  • Soriano, German|||0000-0002-9267-6811
Infections caused by multidrug-resistant organisms (MDRO) are linked to poor outcomes, particularly in patients with cirrhosis. The underlying mechanisms are not fully understood and may involve a different immune response against MDRO. This study aimed to compare the in vitro immune response between multidrug-resistant (MDR) Escherichia coli and antibiotic-susceptible E. coli strains. Surface protein extract and DNA extract were obtained from MDR E. coli (n = 6) and antibiotic-susceptible E. coli (n = 6) strains isolated from infected patients with cirrhosis. The extracts were used to stimulate in vitro peripheral blood mononuclear cells from healthy donors. After 48 h, cytokine levels (IFN-γ, IL-1β, IL-10, IL-12p70, MCP-1, IL-8, IL-6, MIP-1α, and MIP-1β) were measured. We observed no significant differences in cytokine production between MDR and susceptible strains. However, we identified notable interindividual variability in cytokine production for most of the cytokines studied. Only IFN-γ and IL-6 in surface extract and MCP-1 in DNA extract showed similar levels across all donors. We conclude that the cytokine profiles induced by MDR E. coli in vitro were similar to those in susceptible strains. These findings suggest that the poor prognosis associated with MDR E. coli infections is not due to a differential immune response but rather to other factors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Alcohol-associated liver disease, Natural history, management and novel targeted therapies

  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Pose, Elisa|||0000-0002-0224-7686
  • Gratacós Ginès, Jordi|||0000-0003-1181-7238
  • Clemente-Sanchez, Ana
  • López-Pelayo, Hugo|||0000-0002-3850-8374
  • Bataller, Ramon|||0000-0002-1119-7799
Alcohol consumption is a leading cause of preventable morbidity and mortality worldwide and the primary cause of advanced liver disease. Alcohol use disorder is a chronic, frequently relapsing condition characterized by persistent alcohol consumption despite its negative consequences. Alcohol-associated liver disease (ALD) encompasses a series of stages, from fatty liver (steatosis) to inflammation (steatohepatitis), fibrosis, and, ultimately, liver cirrhosis and its complications. The development of ALD is complex, involving both genetic and environmental factors, yet the exact mechanisms at play remain unclear. Alcohol-associated hepatitis (AH), a severe form of ALD, presents with sudden jaundice and liver failure. Currently, there are no approved targeted therapies able to interfere in the pathogenesis of ALD to stop the progression of the disease, making alcohol abstinence the most effective way to improve prognosis across all stages of ALD. For patients with advanced ALD who do not respond to medical therapy, liver transplantation is the only option that can improve prognosis. Recently, AH has become an early indication for liver transplantation in non-responders to medical treatment, showing promising results in carefully selected patients. This review provides an update on the epidemiology, natural history, pathogenesis, and current treatments for ALD. A deeper insight into novel targeted therapies investigated for AH focusing on new pathophysiologically-based agents is also discussed, including anti-inflammatory and antioxidative stress drugs, gut-liver axis modulators, and hepatocyte regenerative molecules.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease

  • Brujats Rubirola, Anna|||0000-0003-3317-0295
  • Huerta, Anna|||0000-0002-2524-770X
  • Osuna Gómez, Rubén|||0000-0003-2875-4405
  • Guinart Cuadra, Albert|||0000-0003-0233-5595
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Pujol Camps, Clàudia|||0000-0002-3238-2547
  • Soriano, German|||0000-0002-9267-6811
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Fajardo Ordoñez, Javier|||0009-0001-7716-1908
  • Escorsell, Àngels|||0000-0001-5083-8467
  • Gallego Moya, Adolfo|||0000-0002-8423-6787
  • Vidal, Silvia|||0000-0002-3909-6682
  • Villanueva, Càndid|||0000-0002-3674-914X
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
Advanced chronic liver disease (ACLD) is associated with a wide spectrum of immune dysfunction. The clinical impact of SARS-CoV-2 on the development of decompensation and immune response in unvaccinated outpatients has not as yet been clearly defined. This study aimed to evaluate the clinical and immunological impact of SARS-CoV-2 on outpatients with ACLD. This is an observational case-control study, in which ACLD outpatients were included prospectively and consecutively and classified into two groups: SARS-CoV-2 infected and non-infected. Patients' baseline characteristics and infection data were collected and analyzed. Immunoglobulin G (IgG) levels against Spike 1 were evaluated. The primary endpoint was risk of liver decompensation during follow-up, assessed after propensity score matching and adjusted by Cox regression. Between October 2020 and July 2021, ACLD outpatients (n = 580) were identified, and 174 patients with clinical follow-up were included. SARS-CoV-2 infection incidence was 7.6% (n = 44). Risk of liver decompensation was significantly higher after infection (HR = 2.43 [1.01-5.86], p = 0.048) vs. non-infection. The time of IgG evaluation was similar in all patients (n = 74); IgG concentrations were significantly higher in compensated vs. decompensated patients (1.02 ± 0.35 pg/mL vs. 0.34 ± 0.16 pg/mL, p < 0.0001) and correlated with hemoglobin levels. The dysregulation of the innate immune response in patients with decompensated liver disease increased the risk of further decompensation following SARS-CoV-2, mainly due to a worsening of ascites.